[HTML][HTML] Anthracycline-induced cardiotoxicity—are we about to clear this hurdle?

WCM Dempke, R Zielinski, C Winkler… - European Journal of …, 2023 - Elsevier
Anthracyclines have contributed significantly to remarkable improvements in overall survival
and are regarded as the most effective cytostatic drug for cancer treatment in various …

Cardiotoxicity linked to anticancer agents and cardioprotective strategy

SI Khairnar, YA Kulkarni, K Singh - Archives of Pharmacal Research, 2022 - Springer
Chemotherapy is a main treatment for cancer, and it benefits patients by controlling cancer
relapse and metastasis, thereby leading to an increase in the overall survival rate. However …

Association of non-high-density lipoprotein to high-density lipoprotein ratio (NHHR) with prognosis in cancer survivors: a population-based study in the United States

W Xie, H Liu, Q Lin, L Lian, B Liang - Frontiers in Nutrition, 2024 - frontiersin.org
Background Patients with cancer frequently exhibit alterations in serum lipid profiles
associated with chemotherapy. It has been reported that lipid distribution in cancer …

Fasting: A Complex, Double-Edged Blade in the Battle Against Doxorubicin-Induced Cardiotoxicity

Y Meng, J Sun, G Zhang, T Yu, H Piao - Cardiovascular Toxicology, 2024 - Springer
In recent years, there has been a surge in the popularity of fasting as a method to enhance
one's health and overall well-being. Fasting is a customary practice characterized by …

Possibilities of dapagliflozin-induced cardioprotection on doxorubicin+ cyclophosphamide mode of chemotherapy-induced cardiomyopathy

A Avagimyan, M Sheibani, N Pogosova… - International Journal of …, 2023 - Elsevier
Rationale The global burden of cardiovascular (CV) and oncological diseases continues to
increase. In this regard, the prevention of CV diseases (CVD) before and after cancer …

[HTML][HTML] Doxorubicin-induced cardiotoxicity and risk factors

C Belger, C Abrahams, A Imamdin, S Lecour - IJC Heart & Vasculature, 2024 - Elsevier
Doxorubicin (DOX) is an anthracycline antibiotic widely used as a chemotherapeutic agent
to treat solid tumours and hematologic malignancies. Although useful in the treatment of …

Multimodality imaging in cardio-oncology: the added value of CMR and CCTA

C Lisi, F Catapano, P Rondi, S Figliozzi… - The British Journal of …, 2023 - academic.oup.com
During the last 30 years, we have assisted to a great implementation in anticancer treatment
with a subsequent increase of cancer survivors and decreased mortality. This has led to an …

A Triphenylphosphonium-Functionalized Delivery System for an ATM Kinase Inhibitor That Ameliorates Doxorubicin Resistance in Breast Carcinoma Mammospheres

V Stagni, A Kaminari, C Contadini, D Barilà, RL Sessa… - Cancers, 2023 - mdpi.com
Simple Summary Doxorubicin (DOX) is widely used in the treatment of breast cancer.
However, resistance limits its effectiveness. In particular, breast cancer stem cells (BCSCs) …

Role of Statin Therapy in Prevention of Anthracycline-Induced Cardiotoxicity: A three dimentional echocardiography study

AL Mohamed, AA El-Abd, HG Mohamed… - Current Problems in …, 2024 - Elsevier
Background Recent advances in the treatment of breast cancer have resulted in improved
overall cancer survival; however, cancer therapy related cardiac dysfunction is considered a …

Extracellular vesicle-based formulation of doxorubicin: drug loading optimization, characterization, and cytotoxicity evaluation in tumor spheroids

F Mehryab, M Ebrahimi, H Baharvand… - Pharmaceutical …, 2024 - Taylor & Francis
Doxorubicin (DOX) is a chemotherapeutic with considerable efficacy, but its application is
limited due to cardiotoxicity. Nanoparticles can improve DOX efficacy and prevent its …